Document:

Letter Agreement

 Exhibit 10.1 
 Yukoh Yoshida 
 President 
 Senju Pharmaceutical Co., Ltd. 
 5-8, Hiranomachi 2-chome 
 Chuo-ku, Osaka, 541-0046 
 Japan 
 Dear Mr. Yoshida: 
 In
connection with our recent letter regarding changing the terms and conditions of the Bromfenac License Agreement dated March 7, 2002, and amended August 13, 2002 and May 31, 2006, this letter is to further document our mutual
agreement to the following additional change. 
 Senju and ISTA agree that the definition of Territory in the License Agreement
is amended to read: 
 1.02 “Territory” shall mean North America, including the possessions of the United
States.” 
 If you agree to the above, please sign and date this and the duplicate copy of this letter in the space
provided below and return one signed copy to us. 
 Sincerely yours, 
 /s/ Vicente Anido, Jr. 
 Vicente Anido, Jr. 
 President and CEO 
 ISTA Pharmaceuticals, Inc.

 Date: December 11, 2009 
 Agreed to and accepted 
 /s/ Yukoh Yoshida 
 Yukoh Yoshida 
 President 
 Senju Pharmaceutical Co., Ltd.Letter Agreement

 Exhibit 10.2 
 CONFIDENTIAL PORTIONS HAVE BEEN OMITTED BASED UPON A REQUEST FOR 
 CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE 
 ACT OF 1934 AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND 
 EXCHANGE COMMISSION 
 SENJU PHARMACEUTICAL CO., TD. 
 2-5-8, HIRANOMACHI, CHUO-KU, OSAKA 541-0046, JAPAN 
 TEL:+81-6-6201-9698
FAX:+81-6-6226-0406 
 December 11, 2009 
 Mr. Vicente Anido, Jr. 
 President and CEO 
 ISTA Pharmaceuticals, Inc. 
 15295 Alton Parkway 
 Irvine, CA 92618 
 United States of America

 Dear Mr. Anido: 
 We have investigated the feasibility of changing the terms and conditions of the Bromfenac License Agreement dated March 7, 2002 and amended on August 13, 2002 and May 31, 2006 following the recent conversation with you.

 Senju agrees to delete the last sentence of the definition of Net Sales: “Provided, however, that such reductions will
be less than [*]% of the gross invoiced price”. That new Net Sales definition would be applied to the royalties generated from January 1, 2010. 
 In exchange for this, we require the addition of a new paragraph regarding assistance to be provided by ISTA for development outside the Territory such as: “Upon the request of Senju, ISTA shall
cooperate with Senju and/or the Third Party designated by Senju for the necessary activities for obtaining governmental approval of bromfenac ophthalmic preparation in the countries or areas of Europe, the Middle East, and South America. ISTA shall
not be obligated to conduct any additional pre-clinical studies, clinical studies or data analyses even if necessary to obtain governmental approvals outside the Territory, it being the intent of the parties that ISTA’s activities shall be
limited to making available information it already has in its possession or control. Such activities include accepting inspectors from the following governmental authorities: (1) the European Medicines Agency, (2) the Medicines and
Healthcare products Regulatory Agency, and (3) Therapeutic Goods Administration (for the EU, the UK, and Australia respectively, and other countries relying on such agencies’ inspections). ISTA may limit such inspections of its clinical
investigational sites to no more than three site inspections for each agency. Neither ISTA nor its clinical investigational sites shall be obligated to retain records for any period longer than that required by the U.S. Food and Drug
Administration.” 
 Provided, however that the above change in the definition of the Net Sales, as well as the duties and
obligations of ISTA under the preceding paragraph, are contingent on the timely receipt and acceptance by the European Medicines Agency of the written statements required from ISTA and its clinical investigators such that the European Medicines
Agency can conduct its GCP Inspections pursuant to the centralized Application with EMEA Reference No. EMEAMJC/001198. Should the EMEA acceptance be delayed beyond January 1, 2010 then the new Net Sales definition would likewise be delayed
until the date that such approval is received and acknowledged by Senju and ISTA. In this case, ISTA would not commence support of activities outside of the Territory until such approval is received. 
  

	*	CONFIDENTIAL PORTION OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Senju and ISTA will execute amendments or supplemental memoranda to the Bromfenac License
Agreement in confirmation of this letter. 
 If you agree to the above, please sign and date this and the duplicate copy of this
letter in the space provided below and return one signed copy to us. 
  

			
	Sincerely yours	 	Agreed and Accepted
		
	/s/ Yukoh Yoshida	 	/s/ Vicente Anido, Jr.
		
	Yukoh Yoshida	 	Vicente Anido, Jr.
	President	 	President and CEO
	Senju Pharmaceutical Co., Ltd.	 	ISTA Pharmaceuticals, Inc.Loan Modification Agreement

 Exhibit 10.3 
 LOAN MODIFICATION AGREEMENT 
 This Loan Modification
Agreement is entered into as of December 16, 2009, by and between ISTA PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”) and SILICON VALLEY BANK (“Bank”). 
 1. DESCRIPTION OF EXISTING INDEBTEDNESS: Among other indebtedness which may be owing by Borrower to Bank, Borrower is indebted to Bank pursuant to,
among other documents, a Loan and Security Agreement, dated on or about December 16, 2005, as may be amended from time to time, (the “Loan Agreement”). Defined terms used but not otherwise defined herein shall have the same meanings
as in the Loan Agreement. 
 Hereinafter, all indebtedness owing by Borrower to Bank shall be referred to as the “Indebtedness.”

 2. DESCRIPTION OF COLLATERAL. Repayment of the Indebtedness is secured by the Collateral as described in the Loan Agreement.

 Hereinafter, the above-described security documents, together with all other documents securing repayment of the Indebtedness shall be
referred to as the “Security Documents”. Hereinafter, the Security Documents, together with all other documents evidencing or securing the Indebtedness shall be referred to as the “Existing Loan Documents”. 
 3. DESCRIPTION OF CHANGE IN TERMS. 
  

	 	A.	Modification to Loan Agreement. 

  

	 	1.	Section 2.5(b) is hereby amended and restated in its entirety to read as follows: 

 (b) Advances. Each Advance shall bear interest on the outstanding principal amount thereof from the date when made, continued or
converted until paid in full at a rate per annum equal to the greater of (a) the Prime Rate plus the Prime Rate Margin, and (b) 4.25 percentage points (425 basis points). Pursuant to the terms hereof, interest on each Advance shall be paid
in arrears on each Interest Payment Date. Interest shall also be paid on the date of any prepayment of any Advance pursuant to this Agreement for the portion of any Advance so prepaid and upon payment (including prepayment) in full thereof. All
accrued but unpaid interest on the Advances shall be due and payable on the Revolving Line Maturity Date. 
  

 1 

	 	2.	Section 6.6(b) is hereby amended and restated in its entirety to read as follows: 

 (b) Borrower shall maintain, on a consolidated basis with respect to Borrower and its Subsidiaries measured quarterly, Tangible Net Worth of
at least $30,000,000. 
  

	 	3.	The definition of “Borrowing Base” in Section 13.1 is hereby amended and restated to read as follows: 

 “Borrowing Base” is (a) 80% of Eligible Accounts plus (b) 25% of Net Cash (up to $10,000,000), as determined by
Bank from Borrower’s most recent Borrowing Base Certificate; provided, however, that Bank may decrease the foregoing percentages in its good faith business judgment based on events, conditions, contingencies, or risks which, as
determined by Bank, may adversely affect Collateral. 
  

	 	4.	Clause (e) of the definition of “Eligible Accounts” in Section 13.1 is hereby amended and restated to read as follows: 

 (e) Accounts owing from an Account Debtor, including Affiliates, whose total obligations to Borrower exceed twenty-five percent
(25%) of all Accounts (provided that such concentration percentage shall be limited to $10,000,000 in the aggregate as to the Accounts due from Account Debtors Amerisource Bergen, Cardinal Health, Inc., and McKesson Corp.), for the amounts that
exceed that percentage (or aggregate dollar limitation, if applicable), unless Bank approves in writing; 
  

	 	5.	The definition of “Prime Rate Margin” in Section 13.1 is hereby amended and restated in its entirety to read as follows: 

 “Prime Rate Margin” is one-fourth (0.25) of a percentage point (25 basis points). 
  

	 	6.	The definition of “Revolving Line Maturity Date” in Section 13.1 is hereby amended and restated in its entirety to read as follows:

 “Revolving Line Maturity Date” is the earlier of (a) December 30, 2010; and
(b) the date Bank exercises its remedies under Section 9.1(a). 
  

	 	7.	A new definition of “Tangible Net Worth” is hereby added to Section 13.1 which shall read as follows: 

 “Tangible Net Worth” means on any date, the consolidated total assets of Borrower and its Subsidiaries minus (a) any
amounts attributable to (i) goodwill, (ii) intangible items including

  

 2 

 
unamortized debt discount and expense, patents, trade and service marks and names, copyrights and research and development expenses except prepaid expenses, (iii) notes, accounts receivable
and other obligations owing to Borrower from its officers or other Affiliates, and (iv) reserves not already deducted from assets, minus (b) Total Liabilities, plus (c) Subordinated Debt, plus (d) liabilities in connection with
Warrants issued by Borrower in connection with, and as defined under, the $65,000,000 Facility Agreement, dated September 26, 2008, to Deerfield Private Design Fund, L.P., and the other lenders thereunder. 
  

	 	8.	The form of Compliance Certificate is hereby replaced with Exhibit D attached hereto and the form of Borrowing Base Certificate is hereby replaced with Exhibit F
attached hereto. 

  

	4.	CONSISTENT CHANGES. The Existing Loan Documents are hereby amended wherever necessary to reflect the changes described above. 

  

	5.	NO DEFENSES OF BORROWER. Borrower agrees that, as of the date hereof, it has no defenses against the obligations to pay any amounts under the Indebtedness.

  

	6.	CONTINUING VALIDITY. Borrower understands and agrees that in modifying the existing Indebtedness, Bank is relying upon Borrower’s representations,
warranties, and agreements, as set forth in the Existing Loan Documents. Except as expressly modified pursuant to this Loan Modification Agreement, the terms of the Existing Loan Documents remain unchanged and in full force and effect. Bank’s
agreement to modifications to the existing Indebtedness pursuant to this Loan Modification Agreement in no way shall obligate Bank to make any future modifications to the Indebtedness. Nothing in this Loan Modification Agreement shall constitute a
satisfaction of the Indebtedness. 

  

	7.	CONDITIONS. The effectiveness of this Loan Modification Agreement is conditioned upon the execution and delivery of this Modification Agreement and the receipt
by Bank of a loan modification fee in the amount of $62,500. 

 This Loan Modification Agreement is executed as of
the date first written above. 
  

									
	 BORROWER:
  
 ISTA PHARMACEUTICALS, INC.
	 		 	 BANK:
  
 SILICON VALLEY BANK

					
	By:	 	/s/ Lauren P. Silvernail	 		 	By:	 	/s/ Brett Maver
					
	Name:	 	 Lauren P. Silvernail
	 		 	Name:	 	Brett Maver
					
	Title:	 	 CFO & VP Corporate Development
	 		 	Title:	 	Relationship Manager

  

 3 

 EXHIBIT D 
 COMPLIANCE CERTIFICATE 
  

			
	 TO: SILICON VALLEY BANK
	 	Date:                                      
                   

 FROM: ISTA PHARMACEUTICALS, INC. 
 The undersigned authorized officer of ISTA PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”) certifies that under the terms and conditions of the Loan and Security Agreement between
Borrower and Bank (the “Agreement”), (1) Borrower is in complete compliance for the period ending _______________ with all required covenants except as noted below, (2) there are no Events of Default, (3) all representations
and warranties in the Agreement are true and correct in all material respects on this date except as noted below; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are
qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date,
(4) Borrower, and each of its Subsidiaries, has timely filed all required tax returns and reports, and Borrower has timely paid all foreign, federal, state and local taxes, assessments, deposits and contributions owed by Borrower except as
otherwise permitted pursuant to the terms of Section 5.9 of the Agreement, and (5) no Liens have been levied or claims made against Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits of which Borrower has
not previously provided written notification to Bank. Attached are the required documents supporting the certification. The undersigned certifies that these are prepared in accordance with generally GAAP consistently applied from one period to the
next except as explained in an accompanying letter or footnotes. The undersigned acknowledges that no borrowings may be requested at any time or date of determination that Borrower is not in compliance with any of the terms of the Agreement, and
that compliance is determined not just at the date this certificate is delivered. Capitalized terms used but not otherwise defined herein shall have the meanings given them in the Agreement. 
 Please indicate compliance status by circling Yes/No under “Complies” column. 
  

					
	 Reporting Covenant
	 	Required	 	Complies
	 	 	 
	 Monthly financial statements with Compliance
Certificate
	 	Monthly within 30 days	 	Yes No
	 	 	 
	 10-Q, 10-K and 8-K
	 	Within 5 days after filing with SEC	 	Yes No
	 	 	 
	 Borrowing Base Certificate, A/R & A/P
Agings
	 	Monthly within 20 days if borrowing	 	Yes No

  

 4 

							
	Financial Covenant	  	Required	  	Actual	  	Complies
	 Maintain:
	  	 	  	 	  	 
	 Minimum Adjusted Quick Ratio, Monthly

	  	1.25:1.00	  	_____:1.0	  	Yes No
	 Minimum Tangible Net Worth, Quarterly

	  	$30MM	  	$_______	  	Yes No

 The following financial covenant analyses and information set forth in Schedule 1 attached hereto are
true and accurate as of the date of this Certificate. 
 The following are the exceptions with respect to the certification above: (If no
exceptions exist, state “No exceptions to note.”) 
  
  
  
  
  
  
  
  
  

									
	ISTA PHARMACEUTICALS, INC.	 		 	BANK USE ONLY
					
	By:	 	 	 		 	Received by:	 	 
	Name:	 	 	 		 		 	AUTHORIZED SIGNER
	Title:	 	 	 		 	Date:	 	 
		 		 		 	Verified:	 	 
		 		 		 		 	AUTHORIZED SIGNER
		 		 		 	Date:	 	 
		 		 		 	Compliance Status:    Yes    No

  

 5 

 Schedule 1 to Compliance Certificate 
 Financial Covenants of Borrower 
 Dated: ____________________ 
  

	I.	Adjusted Quick Ratio (Section 6.6(a)) 

 Required:        1.25:1.00 
 Actual: 
  

						
			
	 A.
	  	Aggregate value of the unrestricted cash and cash equivalents of Borrower and its Subsidiaries	  	$	                
			
	 B.
	  	Aggregate value of the net billed accounts receivable of Borrower and its Subsidiaries	  	$	 
			
	 C.
	  	Aggregate value of the Investments with maturities of fewer than 12 months of Borrower and it Subsidiaries	  	$	 
			
	 D.
	  	Quick Assets (the sum of lines A through C)	  	$	 
			
	 E.
	  	Aggregate value of Obligations to Bank	  	$	 
			
	 F.
	  	Aggregate value of liabilities of Borrower and its Subsidiaries (including all Indebtedness) that matures within one (1) year	  	$	 
			
	 G.
	  	Current Portion of Subordinated Debt	  	$	 
			
	 H.
	  	Current Liabilities (the sum of lines E and F less G)	  	$	 
			
	 I.
	  	Value of Line D (Quick Assets)	  	$	 
			
	 J.
	  	Value of Line H (Current Liabilities)	  	$	 
			
	 K.
	  	Aggregate value of all amounts received or invoiced by Borrower in advance of performance under contracts and not yet recognized as revenue	  	$	 
			
	 L.
	  	Line J minus line K	  	$	 
			
	 M.
	  	Adjusted Quick Ratio (line I divided by line L)	  		

 Is line M equal to or greater than 1.25:1.00? 
  

			
	                  No, not in compliance

	 	                Yes, in compliance

  

 6 

	II.	Tangible Net Worth (Section 6.6(b)) 

 Required:        See below 
 Actual: 
  

					
			
	A.	  	Aggregate value of liabilities of Borrower and its Subsidiaries (including all Indebtedness and Warrant liability associated with the Deerfield Facility Agreement) and current
portion of Subordinated Debt permitted by Bank to be paid by Borrower (but no other Subordinated Debt)	  	$                
			
	B.	  	Aggregate value of Indebtedness of Borrower subordinated to Borrower’s Indebtedness to Bank and Warrant liability associated with the Deerfield Facility Agreement	  	$                
			
	C.	  	Debt (line A minus line B)	  	$                
			
	D.	  	Aggregate value of total assets of Borrower and its Subsidiaries	  	$                
			
	E.	  	Aggregate value of goodwill of Borrower and its Subsidiaries	  	$                
			
	F.	  	Aggregate value of intangible assets of Borrower and its Subsidiaries	  	$                
			
	G.	  	Aggregate value of any reserves not already deducted from assets	  	$                
			
	H.	  	Value of line C	  	$                
			
	I.	  	Tangible Net Worth (line D minus line E minus line F minus line G minus line H)	  	$                

 Is line I greater than or equal to $30,000,000? 
  

			
	                  No, not in compliance

	 	                 Yes, in compliance

  

 7 

 EXHIBIT F 
 BORROWING BASE CERTIFICATE 
  
  
 Borrower: ISTA Pharmaceuticals, Inc. 
 Lender: Silicon Valley Bank 
 Commitment
Amount:        $25,000,000 
 ACCOUNTS RECEIVABLE 
  

					
			
	1.	 	Total Accounts Receivable as of ____________________	  	$_______________
			
	2.	 	Less Ineligible Accounts Receivable	  	$_______________
			
	3.	 	TOTAL Eligible Accounts Receivable (#1 minus #2)	  	$_______________
			
	4.	 	Eighty percent (80%) of Eligible Accounts Receivable	  	$_______________
			
	5.	 	Net Cash as of _____________	  	$_______________
			
	6.	 	Twenty-five percent (25%) of Net Cash	  	$_______________
			
	7.	 	Maximum Loan Amount (lesser of (a) $25,000,000 and (b) #4 plus the lesser of (X) $10,000,000 million and (Y) #6)	  	$_______________
			
	8.	 	Present balance owing on Line of Credit	  	$_______________
			
	9.	 	Amounts outstanding or reserved under Letter of Credit Sublimit, FX Reserve and Cash Management Services Sublimit	  	$_______________
			
	10.	 	#8 plus #9	  	$_______________
			
	11.	 	LOAN AVAILABILITY (#7 minus #10)	  	$_______________

 The undersigned represents and warrants that this is true, complete and correct, and that the
information in this Borrowing Base Certificate complies with the representations and warranties in the Loan and Security Agreement between the undersigned and Silicon Valley Bank. 
  

					
	 COMMENTS:
  
 By: ___________________________
                     Authorized Signer
 Date: _________________________
	  		  	 BANK USE ONLY
  
 Received by:
_____________________
                         AUTHORIZED SIGNER
 Date: __________________________
 Verified: ________________________
                 AUTHORIZED SIGNER
 Date: ___________________________
 Compliance Status:    Yes        No

  

 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}]]